Juno Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Juno Therapeutics Inc
Subsidiary
Industry Biotechnology
Founded 2013[1]
Headquarters Seattle, WA
Key people

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Mark Gilbert, M.D. (CMO)
Parent Celgene
Website junotherapeutics.com

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[1] The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.[2]

History[edit]

In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.[3]

In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates.[4] In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million.[5] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas.[6] In June, the company announced it would acquire X-Body for more than $44 million.[7] In June, the company announced a 10-year partnership with Celgene valued at $1 billion.[8] As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.[9]

In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets.[10] Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million.[11] This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.[12]

In January 2018, Celgene announced it would acquire Juno for $9 billion.[13]

Juno Therapeutics

 

AbVitro
(Acq 2016)



 

RedoxTherapies
(Acq 2016)




Pipeline[edit]

Drug Notes
JCAR014 Targeted at CD19. Currently in Phase I/II trials at the Fred Hutchison Cancer Research Center, tested for relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia.[14]
JCAR015 Targeted at CD19.[15] Designed to treat acute lymphoblastic leukemia (ALL).
In 2014 in Phase I trials with Memorial Sloan Kettering Cancer Centre; Received Orphan Drug Designation By FDA in November 2014.[16]
In 2016 was in phase II trial for ALL.[15]

In 2016 was paused twice after patient deaths[17]
In 2017 was halted.[18]

JCAR017 Targeted at CD19. Currently in Phase I/II trials at Seattle Children's Hospital, tested for pediatric and young adult relapsed/refractory CD19 positive leukemia.[19] Also known as Lisocabtagene maraleucel.[20]
JTCR016 Targeted at WT-1. Currently in Phase I for adult acute myeloid leukemia.[21]
JCAR023 Targeted at L1CAM. Currently in Phase I for Pediatric neuroblastoma.[21]
JCAR018 Targeted at CD22.Currently in Phase I for non-Hodgkin's lymphoma and acute lymphoblastic leukemia.[21]
others two more in phase I by mid 2016.[21]

References[edit]

  1. ^ a b "News Release". Juno Therapeutics. 
  2. ^ Lombardo, Cara (2018-01-22). "Celgene to Buy Juno Therapeutics for $9 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 2018-01-22. 
  3. ^ "News Release". Juno Therapeutics. 
  4. ^ "MedImmune, Juno Team Up to Study Cancer Immunotherapy Combo". GEN. 
  5. ^ "Juno Therapeutics Buys Stage Cell Therapeutics for Up-to-$233M". GEN. 
  6. ^ Staff (May 27, 2015). "Juno, Editas Launch Up-to-$737M+ Cancer Therapy Collaboration". Genetic Engineering & Biotechnology News. Retrieved 2016-02-11. open access publication – free to read
  7. ^ "Juno Therapeutics Acquires X-Body for $44M+". GEN. 
  8. ^ "Celgene Launches $1B Immunotherapy Collaboration with Juno". GEN. 
  9. ^ Doni Bloomfield (29 June 2015). "Juno Rises as Celgene Pays $1 Billion to Buy Cancer Stake". Bloomberg.com. 
  10. ^ "Juno's AbVitro Acquisition Adds Sequencing to Repertoire - GEN". GEN. Retrieved 24 August 2017. 
  11. ^ "Juno Buys RedoxTherapies for $10M+ - GEN". GEN. Retrieved 24 August 2017. 
  12. ^ "Juno Licenses BCMA from MSK, Eureka Therapeutics - GEN". GEN. Retrieved 24 August 2017. 
  13. ^ https://www.reuters.com/article/us-biotech-m-a/biotech-ma-takes-off-as-sanofi-and-celgene-spend-20-billion-idUSKBN1FB20V
  14. ^ "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia". clinicaltrials.gov. 
  15. ^ a b "Juno Seeks Trial Protocol Change Following Patient Deaths - GEN". GEN. Retrieved 24 August 2017. 
  16. ^ "Juno's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA". Juno Therapeutics. 18 Nov 2014. 
  17. ^ "Two patient deaths halt trial of Juno's new approach to treating cancer". STAT. 
  18. ^ "Juno Accelerates Development of JCAR017, Halts JCAR015". OncLive. 
  19. ^ "A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia". clinicaltrials.gov. 
  20. ^ Lisocabtagene maraleucel shows promise for pretreated non-Hodgkin lymphoma
  21. ^ a b c d "Pipeline". Juno Therapeutics.